Results 191 to 200 of about 92,765 (246)

Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study

Gut, 2020
Objective Direct comparison of the clinical outcomes between nucleos(t)ide analogue (NA) discontinuation versus NA continuation has not been performed in patients with chronic hepatitis B who achieved HBsAg-seroclearance.
M. A. Kim, Seung-Up Kim, D. Sinn, J. Jang, Y. Lim, S. Ahn, Jae-Jun Shim, Y. Seo, Y. Baek, Sang Gyune Kim, Y. S. Kim, J. H. Kim, W. Choe, H. Yim, Hyun Woong Lee, J. Kwon, S. Lee, J. Jang, Hwi-Young Kim, Yewan Park, Gi-Ae Kim, Hyun Yang, H. Lee, Myeongseok Koh, Young-Sun Lee, Min-Kuk Kim, Young Chang, Y. Kim, Jung‐Hwan Yoon, F. Zoulim, Jeong‐Hoon Lee   +30 more
semanticscholar   +1 more source

Kidney Transplantation from HBsAg+ Living Donors to HBsAg- Recipients: Clinical Outcomes at a High-volume Center in China.

Clinical Infectious Diseases, 2020
BACKGROUND Data on kidney transplantation (KTx) from hepatitis B surface antigen (HBsAg)+ donors to HBsAg- recipients [D(HBsAg+)/R(HBsAg-)] are limited. We aimed to report the outcomes of D(HBsAg+)/R(HBsAg-) KTx in recipients with or without hepatitis B ...
Xianding Wang, Jin-peng Liu, T. Song, Zhong-li Huang, Yu Fan, Yunying Shi, Li-yu Chen, Y. Lv, Zilin Xu, Xiao-hong Li, Li Wang, Tao Lin   +11 more
semanticscholar   +1 more source

Anti-HBe and Subtypes of HBsAg among Asymptomatic HBsAg Carriers

Vox Sanguinis, 1979
Abstract. Finnish HBsAg positive blood donors were analyzed for the HBsAg subtype distribution and the presence of e antigen (HBeAg) and antibody to e (anti‐HBe). 88% (159 of 180) of the donors had subtype ad and 12% (21 of 180) had ay. HBeAg was found in 1% (2 of 180) and anti‐HBe in 74% (133 of 180) of the donors.
P. Ukkonen, K. Penttinen, Vesa Koistinen
openaire   +3 more sources

Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA

Journal of Viral Hepatitis, 2019
The correlation between serum HBcrAg and HBV RNA is unclear, and correlations of intrahepatic cccDNA with HBcrAg, HBV RNA and HBsAg are rarely reported in the same cohort.
E. Chen, Menglan Wang, Y. Tao, Dongbo Wu, J. Liao, Min He, Hong Tang   +6 more
semanticscholar   +1 more source

Polypeptide composition of HBsag

Archives of Virology, 1977
Purified HBsag has a complex structure comprising 8 polypeptides. Some of these polypeptides are immunogenic and induce both humoral and cell-mediated immunity in guinea pigs.
M. Teoharova, Sv. Todorov, E. Mineva, S. Ditzov   +3 more
openaire   +3 more sources

Effects of hepatitis B surface antigen (HBsAg) positivity of donors in HBsAg(+) renal transplant recipients: comparison of outcomes with HBsAg(+) and HBsAg(−) donors

Transplant Infectious Disease, 2016
AbstractAimThe aim of this study was to determine the effects of hepatitis B surface antigen (HBsAg) positivity of the donors on graft survival and liver complications in HBsAg(+) renal transplant recipients.Patients and methodA group of 55 patients who underwent renal transplantation (RTx) in our hospital between 2001 and 2012 were included in the ...
Huseyin Kocak, Vural Taner Yilmaz, Gultekin Suleymanlar, Ibrahim Aliosmanoglu, Burak Veli Ülger, Halil Erbis, Ramazan Cetinkaya   +6 more
openaire   +3 more sources

DETECTION OF HBsAg IN THE PANCREAS

Acta Pathologica Japonica, 1981
Hepatitis B surface antigen (HBsAg) has been reported to be present in other organs than the liver.3,9 So far as our knowledge is concerned, however, any report of cases dealing with pancreatic diseases induced by hepatitis B virus (HBV) has not been described in the English and Japanese literature.
Isamu Sakurai, Tadao Okano, Makoto Yoshimura, Kenji Abe, Toshihiko Shimoda, Toshio Shikata   +5 more
openaire   +3 more sources

Off‐therapy precipitous HBsAg decline predicts HBsAg loss after finite entecavir therapy in HBeAg‐negative patients

Journal of Viral Hepatitis, 2019
Cessation of nucleos(t)ide analogue (Nuc) therapy in HBeAg‐negative patients may increase HBsAg loss rate in patients with sustained remission (SR) and non‐retreated clinical relapsers (CR).
W. Jeng, Ming-Ling Chang, Y. Liaw
semanticscholar   +1 more source

Presence of HBsAg in the Bile of Subjects with Acute HBsAg Viral Hepatitis

Pathobiology, 1975
During acute HB_sAg serum positive viral hepatitis, the surface antigen was not detectable in duodenal bile but was almost always present in gallbladder and hepatic bile when cholecystokinin was intravenously administered. The immunologic nondemonstrability of HB_sAg in duodenal bile is probably due to the ...
L. Cacciatore, Marcello Piazza, V. Molinari, P.T. Cataldo, V. Guadagnino, G. Borgia, G. Manzillo, G. Maio, E. Gravina   +8 more
openaire   +3 more sources

Quantitative Determination of the HBsAg

Vox Sanguinis, 1980
Abstract. HBsAg concentrations down to 0.05 mg/ml can be measured by a quantitative immunoelectrophoresis. By a quantitative radioimmunoassay, HBsAg concentrations from 0.001 mg to 1 mg/ml can be measured.
openaire   +3 more sources